Pacira Pharmaceuticals (PCRX) : Zacks Investment Research ranks Pacira Pharmaceuticals (PCRX) as 3, which is a Hold recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 1.5, which indicates as a Strong Buy.
Pacira Pharmaceuticals (PCRX) : The most positive equity analysts on Pacira Pharmaceuticals (PCRX) expects the shares to touch $105, whereas, the least positive believes that the stock will trade at $59 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $78.13 with an expected fluctuation of $14.49 from the mean.
Pacira Pharmaceuticals (NASDAQ:PCRX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $33.12 and $32.98 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.46. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.21, notching a gain of 5.14% for the day. The total traded volume was 809,194 . The stock had closed at $33.49 on the previous day.
Also, Equity analysts at the Brokerage firm Brean Capital downgrades its rating on Pacira Pharmaceuticals (NASDAQ:PCRX). The rating major has initiated the coverage with hold rating on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on July 1, 2016. The company shares have dropped -49.44% from its 1 Year high price. On Dec 29, 2015, the shares registered one year high at $81.28 and the one year low was seen on Jun 30, 2016. The 50-Day Moving Average price is $42.11 and the 200 Day Moving Average price is recorded at $54.80.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.